
Lupuzor™ Phase III Trials: Partnering With Immupharma
Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having ...Read more >
Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having ...Read more >
Simbec-Orion recently helped a biotech sponsor demonstrate the safety and tolerability of a new trial treatment for idiopathic pulmonary fibrosis ...Read more >
Clinical trials involve a series of studies that test the safety and effectiveness of drugs and other medical treatments. To ...Read more >
Pharmacovigilance is concerned with detecting the possible risks associated with a drug or treatment. Risks are monitored and assessed throughout ...Read more >
In previous years, pharmacology and clinical trials were topics which mainly interested medical professionals, rather than the public. However, as ...Read more >
Clinical pharmacology and therapeutics is the science of medicines and how they are used to diagnose, prevent and treat diseases ...Read more >
In the UK alone, it’s estimated that around 3 million people are living with a rare disease or condition. The ...Read more >
A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered dose inhaler in patients with moderate‑to‑very severe chronic obstructive pulmonary disease. ...Read more >
As a CRO specialising in clinical trials for rare and orphan diseases, Rare Disease Day has become a special cause ...Read more >
Rare Disease Day offers a valuable opportunity to raise awareness of rare disease and campaign for health equity. We are ...Read more >
Vault CTMS and Vault eTMF provide complete visibility into trials, enabling CRO to deliver value-added services to sponsors PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva ...Read more >
Providing oncology drug developers with the successful delivery of early phase oncology studies. Slough, Berkshire, United Kingdom: Simbec-Orion announced a ...Read more >